Put companies on watchlist
CompuGroup Medical SE & Co. KGaA
ISIN: DE000A288904
WKN: A28890
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

CompuGroup Medical SE & Co. KGaA · ISIN: DE000A288904 · EQS - Company News (73 News)
Country: Germany · Primary market: Germany · EQS NID: 1356971
19 May 2022 01:42PM

CompuGroup Medical reports record results at virtual Annual General Meeting and confirms growth targets


DGAP-News: CompuGroup Medical SE & Co. KGaA / Key word(s): AGM/EGM
CompuGroup Medical reports record results at virtual Annual General Meeting and confirms growth targets

19.05.2022 / 13:42
The issuer is solely responsible for the content of this announcement.


Koblenz. CompuGroup Medical SE & Co. KGaA, one of the world's leading e-health companies, held its Annual General Meeting today, once again in a virtual setting. All agenda items were approved by a majority. Management also confirmed the guidance for the current year and medium-term growth targets.

The attendees at the Annual General Meeting, which was once again held virtually, represented around 81 % of CompuGroup Medical’s capital stock. The resolutions on the appropriation of profits and the proposed dividend of EUR 0.50 were approved with a majority of 99.9 %. The Annual General Meeting also approved, with clear majorities of more than 75 % of the votes respectively, the resolutions on the discharge of the General Partner and the Supervisory Board, on the appointment of the auditors, and on an amendment to the Articles of Association, which are intended to allow for greater flexibility in choosing venues for future Annual General Meetings. The resolutions on the compensation report and compensation system for the Managing Directors were also approved with around 75 % more than 69 % of the votes respectively.

In his speech, CEO Dirk Wössner highlighted several examples as to how digitization can make healthcare not only more user-friendly, efficient and effective, but also safer. According to the CEO, solutions that are more user-friendly, more efficient, more effective and, on top of that, safer, generally win through. The healthcare sector is therefore in a state of upheaval worldwide and the e-health sector is a huge growth market with CompuGroup Medical as one of the most important players. This also illustrates the growth potential of the company.

"We have significantly accelerated our organic growth and at the same time decisively strengthened it through strategic acquisitions," said Wössner, summing up the recipe of success in the past fiscal year. "It was an outstanding year of growth for us. We achieved the targets we had set ourselves for 2021, in particular significant revenue growth and very promising organic growth. We exceeded 1,000 million euros in revenue for the first time last year. At 22 percent, revenue growth was almost twice as high as in 2020. And operating profit also rose again: By more than 4 percent to 224 million." And, he emphasized, "we have once again set a revenue record."

Michael Rauch, CFO of CompuGroup Medical, was also satisfied with the results of the past financial year as reflected in his comments: " Free cash flow, which was already very good in the 2020 financial year, was elevated again in the past financial year and exceeded the EUR 100 million threshold for the first time in the history of CompuGroup Medical." And further: "In recent years, we have managed to improve both revenue growth and the quality of revenues generated, reflected in the increased share of recurring revenues, to a new level."

In his speech, CEO Dr. Dirk Wössner accordingly confirmed the guidance for the current fiscal year: "We again expect significant organic growth of 3 to 8 percent in 2022. We are on course for consolidated revenue of more than EUR 1.1 billion. We see adjusted EBITDA at 235 to 260 million euros, corresponding to an adjusted EBITDA margin of between 21 and 24 percent. Our economic course is clearly set on achieving success and growth."

Information on the Annual General Meeting, including the complete voting results, is available at www.cgm.com/agm.

About CompuGroup Medical SE & Co. KGaA

CompuGroup Medical is one of the leading e-health companies in the world. With a revenue base of EUR 1.025 billion in 2021, its software products are designed to support all medical and organizational activities in doctors’ offices, pharmacies, laboratories, hospitals and social institutions. Its information services for all parties involved in the healthcare system and its web-based personal health records contribute towards safer and more efficient healthcare. CompuGroup Medical’s services are based on a unique customer base of more than 1.6 million users, including doctors, dentists, pharmacists and other healthcare professionals in inpatient and outpatient facilities. With locations in 19 countries and products in 56 countries worldwide, CompuGroup Medical is the e-health company with one of the highest coverages among healthcare professionals. More than 8,500 highly qualified employees support customers with innovative solutions for the steadily growing demands of the healthcare system.

Contact for Media Representatives:
Alexander Weimer
Head of Corporate Communications
P +49 261 8000-6100
E-mail: press@cgm.com

Contact for analysts and investors:
Claudia Thomé
Corporate Vice President Investor Relations
P +49 160 3630362
E-mail: claudia.thome@cgm.com



19.05.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: CompuGroup Medical SE & Co. KGaA
Maria Trost 21
56070 Koblenz
Germany
Phone: +49 (0)160 3630362
Fax: +49 (0)261 8000 3200
E-mail: investor@cgm.com
Internet: www.cgm.com
ISIN: DE000A288904
WKN: A28890
Indices: SDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1356971

 
End of News DGAP News Service

1356971  19.05.2022 

fncls.ssp?fn=show_t_gif&application_id=1356971&application_name=news&site_id=boersengefluester_html
Visual performance / price development - CompuGroup Medical SE & Co. KGaA
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.